What CJC-1295 is
CJC-1295 is a growth hormone releasing hormone analog designed to stimulate the GH/IGF-1 axis for longer than native GHRH.
CJC-1295 is grouped under Fitness + Recovery / Longevity + Skin on PeptideFactCheck because it appears frequently in body-composition, recovery, and longevity discussions, especially paired with secretagogues.
The useful starting point is to separate the molecule itself from the internet story around it. It is framed as a way to push the GH/IGF-1 axis rather than taking growth hormone directly.
Why people keep looking it up
People look at CJC-1295 for growth-hormone signaling, body composition, recovery, sleep, and anti-aging claims.
CJC-1295 mimics growth hormone releasing hormone, telling the body to release more growth hormone signal in studied settings.
CJC-1295 tends to stay in the conversation because it touches a familiar public theme: ghrh analog, gh axis, and igf-1. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Human endocrine effects exist, but broad physique, recovery, and longevity claims go beyond what is proven.
Early human studies have evaluated endocrine effects, but that is narrower than most performance claims online.
Mechanistic rationale comes from GHRH signaling and peptide modification for extended exposure.
Why this page carries the current tier: Human endocrine signal exists, but broad optimization claims remain much less settled.
The current seed trail for CJC-1295 is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Potential unknowns include endocrine spillover, glucose effects, edema-like effects, and long-term risk from manipulating the GH axis.
No FDA-approved CJC-1295 drug product is listed in this V1 source trail.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for CJC-1295. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for CJC-1295 is CID 91971820. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 91971820
- Formula
- C165H269N47O46
- Molecular weight
- 3647.2
- InChIKey
- ZUQGTWKGESAQCD-ZGFIGYLBSA-N
Matched synonyms include CJC 1295, 62RC32V9N7, DTXSID501027567, CJC1295, RefChem:918751, DTXCID701513160, GRF 1-29 (CJC1295), 446262-90-4.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for CJC-1295 returns 1 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for CJC-1295 returns 29 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.